Cilostazol This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This page shows you the latest news and research items in this category.
Profile of atherosclerotic risk factors and management in patients of peripheral arterial disease at a tertiary care teaching hospital of North India
The objectives of the present study were to characterize the atherosclerotic risk factor profile and pattern of drug prescription for patients of peripheral arterial disease at a tertiary care teaching hospital and to compare this management with standard guidelines. Data were collected from prescriptions of patients attending cardiothoracic and vascular surgery outpatient department with diagnosis of atherosclerotic peripheral arterial disease from July 2012 to Jun 2013. One hundred twenty prescriptions were analysed. The mean age (±SD) of patients was 53±7.18 years and 23.3% were females. H...
Source: Indian Journal of Pharmaceutical Sciences - December 17, 2014 Category: Drugs & Pharmacology Authors: U AimanMA HaseenMH BegRA KhanFA SiddiquiI Alam Source Type: research
Retrospective review of superficial femoral artery stenting in diabetic patients: thiazolidinedione use may decrease reinterventions
Conclusions: This pilot, translation study demonstrates that diabetic patients taking thiazolidinediones at the time of primary SFA stenting have decreased reintervention rates at 2 years. These results may be explained by higher adiponectin levels or other anti-inflammatory effects in patients taking thiazolidinedione. National and regional quality improvement registries should consider collecting information regarding specific diabetic regimens and use of PPAR agonists such as cilostazol and fibrates. (Source: BMC Cardiovascular Disorders)
Source: BMC Cardiovascular Disorders - December 11, 2014 Category: Cardiology Authors: Karen WalkerDaniel WalshPhilip GoodneySamantha ConnellDavid StoneRichard PowellEva Rzucidlo Source Type: research
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open‐label, parallel‐group trial
DiscussionThe CSPS.com is expected to provide evidence indicating whether secondary IS prevention in high‐risk patients can be improved by using DAPT involving cilostazol. (Source: International Journal of Stroke)
Source: International Journal of Stroke - December 8, 2014 Category: Neurology Authors: Kazunori Toyoda, Shinichiro Uchiyama, Haruhiko Hoshino, Kazumi Kimura, Hideki Origasa, Hiroaki Naritomi, Kazuo Minematsu, Takenori Yamaguchi, Tags: Protocols Source Type: research
The effect of cilostazol and aspirin pre-treatment against subsequent transient focal cerebral ischemia in rat.
We examined whether 7 days of oral administration of cilostazol protects against subsequent cerebral ischemia, and whether or not the effect of combination therapy with aspirin is more protective. METHODS: We used Sprague-Dawley (SD) rats and assigned them to four groups: vehicle, aspirin, cilostazol, and aspirin plus cilostazol combination therapy. After oral administration of anti-platelets for 7 days, we performed transient middle cerebral artery occlusion (MCAO) for 90 minutes, and examined infarct volume, neurological symptoms, and regional cerebral blood flow (rCBF). Immunostaining of Bax, Bcl-2, TUNEL, 4-HNE, 8-...
Source: Neurological Research - December 2, 2014 Category: Neurology Tags: Neurol Res Source Type: research
The response of carotid intima-media thickness to medical treatment is correlated with that of intracranial atherosclerosis.
CONCLUSIONS: The ICAS response may be associated with the CIMT response to medical treatment. PMID: 24285964 [PubMed] (Source: Journal of Clinical Neurology)
Source: Journal of Clinical Neurology - December 2, 2014 Category: Neurology Tags: J Clin Neurol Source Type: research
Contemporary Medical Management of Peripheral Arterial Disease
Peripheral arterial disease (PAD) is primarily caused by progressive systemic atherosclerosis manifesting in the lower extremities. This review addresses the epidemiology, clinical presentation and evaluation, and medical management of PAD, with a focus on intermittent claudication. Key advances in the recognition of cardiovascular risk in asymptomatic individuals with mildly abnormal ankle-brachial index, newer reflections on exercise therapy, and a review of established and investigational agents for the treatment of symptomatic PAD, such as cilostazol, statins, and angiotensin-converting enzyme inhibitors, are highlight...
Source: Cardiology Clinics - November 29, 2014 Category: Cardiology Authors: Kush Agrawal, Robert T. Eberhardt Source Type: research
Topical Cilostazol Inhibits Neointimal Hyperplasia in a Rat Interposition Vein Graft Model
Conclusions: A single intraoperative dose of cilostazol applied locally significantly reduced intima size and smooth muscle content in rat interposition vein grafts examined 4 weeks postoperatively. A topical dose of cilostazol at surgery may therefore be helpful in controlling neointimal hyperplasia and reducing the need for systemic medications to prolong vein graft patency. (Source: Plastic and Reconstructive Surgery)
Source: Plastic and Reconstructive Surgery - November 24, 2014 Category: Cosmetic Surgery Tags: Experimental: Original Articles Source Type: research
Drug-drug interactions associated with antiplatelet therapy.
Authors: Dunn SP, Macaulay TE Abstract Antiplatelet therapy is of paramount importance in the treatment and prevention of adverse cardiovascular events and stroke. Drug-drug interactions (DDIs) among antiplatelet therapies have been growing in both prevalence and clinical importance. Most DDIs with antiplatelet therapies are pharmacodynamic in nature. DDIs with thienopyridines and proton pump inhibitors have resulted in advisories from regulatory agencies although the full significance of this interaction is unknown. Other DDIs with thienopyridines may potentially exist with statins, calcium channel blockers, and w...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research
Cilostazol Attenuates Spinal Cord Ischemia-Reperfusion Injury in Rabbits
The aim of this study was to evaluate the pretreatment effect of cilostazol on spinal cord ischemia-reperfusion injury. (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 19, 2014 Category: Anesthesiology Authors: Yunus Nazli, Necmettin Colak, Mehmet Namuslu, Husamettin Erdamar, Hacer Haltas, Mehmet Fatih Alpay, Omer Nuri Aksoy, Ismail Olgun Akkaya, Omer Cakir Tags: Orıgınal Artıcles Source Type: research
Population Pharmacokinetic Analysis of Diurnal and Seasonal Variations of Plasma Concentrations of Cilostazol in Healthy Volunteers
Conclusions: This study demonstrated the intraday and interseasonal time-varying nature of cilostazol pharmacokinetics using a population modeling approach and developed a strategy for optimizing dosing times. It is suggested that these methods can be similarly applied to analyses and controls of other drugs that exhibit characteristics of time-varying pharmacokinetics. (Source: Therapeutic Drug Monitoring)
Source: Therapeutic Drug Monitoring - November 15, 2014 Category: Drugs & Pharmacology Tags: Original Article Source Type: research
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double‐blind, placebo‐controlled multicenter trial
ConclusionThe SPAD trial is the first study to evaluate the safety and efficacy of dual antiplatelet agents, aspirin plus cilostazol, in comparison with aspirin alone in patients with both ischemic stroke or TIA and PAD. Results from this trial will provide important information on the merit of adding cilostazol to aspirin for slowing down progression of atherosclerosis in patients with ischemic stroke and PAD. (Source: International Journal of Stroke)
Source: International Journal of Stroke - November 14, 2014 Category: Neurology Authors: Jiann‐Shing Jeng, Yu Sun, Jiunn‐Tay Lee, Ruey‐Tay Lin, Chih‐Hung Chen, Helen L. Po, Huey‐Juan Lin, Chung‐Hsiang Liu, Ming‐Hui Sun, Mu‐Chien Sun, Chang‐Ming Chern, Li‐Ming Lien, Hou‐Chang Chiu, Han‐Hwa Hu, Hung‐Yi Chiou, Sien‐Ts Tags: Protocols Source Type: research
Practical Method for Preparing Nanosuspension Formulations for Toxicology Studies in the Discovery Stage: Formulation Optimization and in Vitro/in Vivo Evaluation of Nanosized Poorly Water-Soluble Compounds.
In conclusion, applying a wet media milling method with the combination of HPMC of a small molecular weight and Tween 80 as a dispersing agent, nanosuspensions can be practically prepared and conveniently utilized for enhancing the oral absorption of poorly water-soluble compounds in toxicology studies in the discovery stage. PMID: 25366311 [PubMed - in process] (Source: Chemical and Pharmaceutical Bulletin)
Source: Chemical and Pharmaceutical Bulletin - November 10, 2014 Category: Drugs & Pharmacology Authors: Komasaka T, Fujimura H, Tagawa T, Sugiyama A, Kitano Y Tags: Chem Pharm Bull (Tokyo) Source Type: research
Cilostazol Decreases Cerebral Arterial Pulsatility in Patients with Mild White Matter Hyperintensities: Subgroup Analysis from the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) Study
Conclusions: This study showed that cilostazol decreased cerebral arterial pulsatility in patients with WMH. Our findings indicate the unique effect of cilostazol in small vessel disease (SVD), especially in patients with mild WMH changes. Further clinical trials focusing on WMH volume and clinical outcomes are required to assess the unique efficacy of cilostazol in SVD.Cerebrovasc Dis 2014;38:197-203 (Source: Cerebrovascular Diseases)
Source: Cerebrovascular Diseases - November 7, 2014 Category: Neurology Source Type: research
Cilostazol for intermittent claudication.
CONCLUSIONS: Cilostazol has been shown to be of benefit in improving walking distance in people with intermittent claudication secondary to PAD. Although there is an increase in adverse side effects, they are generally mild and treatable. There is currently insufficient data on whether taking cilostazol results in a reduction of all-cause mortality and cardiovascular events or an improvement in quality of life. Future research into the effect of cilostazol on intermittent claudication should carefully consider comparability, sample size and homogeneity when designing a study. PMID: 25358850 [PubMed - in process] (Sourc...
Source: Cochrane Database of Systematic Reviews - November 5, 2014 Category: Journals (General) Authors: Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G Tags: Cochrane Database Syst Rev Source Type: research
Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC-MS/MS
Publication date: Available online 12 August 2014 Source:Journal of Pharmaceutical Analysis Author(s): Nejal M. Bhatt , Vijay D. Chavada , Daxesh P. Patel , Primal Sharma , Mallika Sanyal , Pranav S. Shrivastav A simple, rapid and sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method has been developed for the simultaneous determination of cilostazol and its pharmacologically active metabolite 3,4-dehydro cilostazol in human plasma using deuterated analogs as internal standards (ISs). Plasma samples were prepared using solid phase extraction and chromatographic separation was perf...
Source: Journal of Pharmaceutical Analysis - November 3, 2014 Category: Drugs & Pharmacology Source Type: research
Cilostazol attenuates ischemia–reperfusion-induced blood–brain barrier dysfunction enhanced by advanced glycation endproducts via transforming growth factor-β1 signaling
Publication date: May 2014 Source:Molecular and Cellular Neuroscience, Volume 60 Author(s): Tomonori Takeshita , Shinsuke Nakagawa , Rie Tatsumi , Gohei So , Kentaro Hayashi , Kunihiko Tanaka , Maria A. Deli , Izumi Nagata , Masami Niwa We investigated the effects of cilostazol, a selective inhibitor of phosphodiesterase 3, on blood–brain barrier (BBB) integrity against ischemia–reperfusion injury enhanced by advanced glycation endproducts (AGEs). We used in vitro BBB models with primarily cultured BBB-related cells from rats (brain capillary endothelial cells, astrocytes and pericytes), and subjected cells to either...
Source: Molecular and Cellular Neuroscience - November 3, 2014 Category: Neuroscience Source Type: research
In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration
Publication date: 10 December 2014 Source:International Journal of Pharmaceutics, Volume 476, Issues 1–2 Author(s): Dina B. Mahmoud , Marwa H. Shukr , Ehab R. Bendas The current investigation was aimed to improve the solubility of poorly soluble drug, cilostazol (CLZ). Self-nanoemulsifying drug delivery system (SNEDDS) composed of oil, surfactant and co-surfactant for both oral and parenteral administration of CLZ was formulated. The components for SNEDDS were identified by solubility studies, and pseudo-ternary phase diagrams were plotted to identify the efficient self-emulsification regions. The optimum formula, comp...
Source: International Journal of Pharmaceutics - November 3, 2014 Category: Drugs & Pharmacology Source Type: research
Effects of ischemic preconditioning and cilostazol on muscle ischemia-reperfusion injury in rats.
CONCLUSIONS: The model of IR caused severe muscle injury in the rat hind limb and ischemic preconditioning has a protective effect, reducing myocyte necrosis, however, treatment with cilostazol and also the association between cilostazol and preconditioning has no protective effect on the skeletal muscle subjected to ischemia and reperfusion injury. PMID: 25351151 [PubMed - in process] (Source: Acta Cirurgica Brasileira)
Source: Acta Cirurgica Brasileira - November 1, 2014 Category: Surgery Authors: Frias Neto CA, Koike MK, Saad KR, Saad PF, Montero EF Tags: Acta Cir Bras Source Type: research
The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry.
Abstract The Korea Acute Myocardial Infarction Registry (KAMIR) was the first nationwide registry data collection designed to track outcomes of patients with acute myocardial infarction (AMI). These studies reflect the current therapeutic approaches and management for AMI in Korea. The results of KAMIR could help clinicians to predict the prognosis of their patients and identify better diagnostic and treatment tools to improve the quality of care. The KAMIR score was proposed to be a predictor of the prognosis of AMI patients. Triple antiplatelet therapy, consisting of aspirin, clopidogrel and cilostazol, was effec...
Source: The Korean Journal of Internal Medicine - November 1, 2014 Category: Internal Medicine Authors: Kim HK, Jeong MH, Lee SH, Sim DS, Hong YJ, Ahn Y, Kim CJ, Cho MC, Kim YJ Tags: Korean J Intern Med Source Type: research
Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes
Drug Development and Industrial Pharmacy, Ahead of Print. (Source: Drug Development and Industrial Pharmacy)
Source: Drug Development and Industrial Pharmacy - October 28, 2014 Category: Drugs & Pharmacology Tags: article Source Type: research
Pharmacological treatment and therapeutic perspectives of metabolic syndrome.
Abstract Metabolic syndrome is a disorder based on insulin resistance. Metabolic syndrome is diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal obesity, elevated blood pressures, elevated glucose, high triglycerides, and low high-density lipoprotein-cholesterol (HDL-C) levels. Clinical implication of metabolic syndrome is that it increases the risk of developing type 2 diabetes and cardiovascular diseases. Prevalence of the metabolic syndrome has increased globally, particularly in the last decade, to the point of being regarded as an epidemic. The prevalence of metabol...
Source: ENDOCR REV - October 24, 2014 Category: Endocrinology Authors: Lim S, Eckel RH Tags: Rev Endocr Metab Disord Source Type: research
Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase
The initiating mechanisms of migraine attacks are very complex but may involve the cyclic AMP signalling pathway. It is unknown whether intracellular cyclic AMP accumulation induces migraine attacks. We investigated whether administration of cilostazol, which causes cyclic AMP accumulation, may induce migraine attacks. We included 14 migraine patients without aura in a double-blind, placebo-controlled crossover study. All participants received oral cilostazol or placebo on two separate days. We recorded migraine headache characteristics, associated symptoms and time of rescue medication intake using a questionnaire. Cilost...
Source: Brain - October 24, 2014 Category: Neurology Authors: Guo, S., Olesen, J., Ashina, M. Tags: Original Articles Source Type: research
Pharmacological treatment and therapeutic perspectives of metabolic syndrome
Abstract Metabolic syndrome is a disorder based on insulin resistance. Metabolic syndrome is diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal obesity, elevated blood pressures, elevated glucose, high triglycerides, and low high-density lipoprotein-cholesterol (HDL-C) levels. Clinical implication of metabolic syndrome is that it increases the risk of developing type 2 diabetes and cardiovascular diseases. Prevalence of the metabolic syndrome has increased globally, particularly in the last decade, to the point of being regarded as an epidemic. The prevalence of metabo...
Source: Reviews in Endocrine and Metabolic Disorders - October 23, 2014 Category: Endocrinology Source Type: research
Colonic diverticular hemorrhage associated with the use of nonsteroidal anti‐inflammatory drugs, low‐dose aspirin, antiplatelet drugs, and dual therapy
ConclusionsBesides alcohol and smoking, NSAIDs, low‐dose aspirin, and antiplatelet drugs are risk factors for diverticular bleeding. The magnitude of risk may differ between different kinds of NSAIDs and antiplatelet drugs, and dual therapy with NSAIDs or antiplatelet drugs increases the risk of bleeding. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - October 15, 2014 Category: Gastroenterology Authors: Naoyoshi Nagata, Ryota Niikura, Tomonori Aoki, Takuro Shimbo, Yoshihiro Kishida, Katsunori Sekine, Shohei Tanaka, Kazuhiro Watanabe, Toshiyuki Sakurai, Chizu Yokoi, Junichi Akiyama, Mikio Yanase, Masashi Mizokami, Naomi Uemura Tags: Gastroenterology Source Type: research
The effects of cilostazol on experimental autoimmune neuritis in Lewis rats
Phosphodiesterase (PDE) is involved in homeostasis, inflammation, tissue regeneration through degradation of cyclic AMP. PDE inhibitor is known to suppress autoimmune inflammatory neurological disease, however, very few report has been published concerning autoimmune peripheral nerve disease. PDE has several isoenzymes and respective selective inhibitors. Some of these inhibitors are already in therapeutical use. PDE-3 inhibitor cilostazole (CLZ) has antiplatelet action and widely used for the prevention of thrombosis. (Source: Journal of Neuroimmunology)
Source: Journal of Neuroimmunology - October 15, 2014 Category: Allergy & Immunology Authors: Wataru Hagiwara, Masashi Inoue, Shingo Konno, Toshiki Fujioka Tags: 108 Source Type: research
GW25-e4606 Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
(Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 13, 2014 Category: Radiology Source Type: research
GW25-e4213 Acute and chronic effects of cilostazol on transient outward potassium current in isolated rat right ventricular myocytes
(Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 13, 2014 Category: Radiology Source Type: research
Inhibitors of PDE4, but Not PDE3, Increase β2-agonist-induced Expression of Anti-inflammatory MKP-1 in Airway Smooth Muscle Cells.
Abstract β2-agonists are principally used in asthma to provide bronchodilation, however they also have anti-inflammatory properties due, in part, to their ability to upregulate mitogen-activated protein kinase phosphatase 1 (MKP-1) in a cAMP-dependent manner. Phosphodiesterases (PDEs) are attractive targets for potentiating the anti-inflammatory response. There are 11 subfamilies of PDE enzymes, among these, inhibition of PDE3 and PDE4 are the main targets for airway smooth muscle (ASM). PDE enzymes are important intracellular regulators that catalyze the breakdown of cAMP and/or cGMP to their inactive forms. Give...
Source: American Journal of Respiratory Cell and Molecular Biology - October 8, 2014 Category: Molecular Biology Authors: Patel BS, Prabhala P, Oliver BG, Ammit AJ Tags: Am J Respir Cell Mol Biol Source Type: research
Cilostazol does not improve peripheral arterial disease‐linked oxidative stress
ConclusionsOur data indicate that cilostazol treatment does not improve oxidative stress in PAD patients after 6 months of treatment. However, lipid peroxidation and total antioxidant capacity were affected by cilostrazol treatment, which could be related to altered reactive oxygen species production. Further research may be needed to determine the critical dose of cilostazol in order to clarify the protective role of this drug in PAD.This article is protected by copyright. All rights reserved. (Source: Cardiovascular Therapeutics)
Source: Cardiovascular Therapeutics - October 1, 2014 Category: Cardiology Authors: M Rosa Bernal‐Lopez, Daniel Peña, Pilar Gomez‐Martin, Francisco J Tinahones, Ricardo Gomez‐Huelgas Tags: Original Research Article Source Type: research
The phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomy
Abstract Liver failure after extended hepatectomy represents a major challenge in the surgery of hepatic colorectal metastasis. A previous study has indicated that inhibition of phosphodiesterase type 3 (PDE 3) stimulates liver regeneration. However, little is known whether PDE 3 inhibitors, such as cilostazol, also stimulate the growth of remnant metastases. Therefore, we herein studied the effect of cilostazol on engraftment, vascularization and growth of colorectal liver metastasis after major hepatectomy. WAG-rats underwent either major hepatectomy or sham operation. Metastases were induced by subcapsular imp...
Source: Clinical and Experimental Metastasis - October 1, 2014 Category: Cancer & Oncology Source Type: research
Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: Implication of cilostazol for diabetes mellitus-induced dementia.
In conclusion, diabetes can aggravate cognitive dysfunction in vascular dementia, and PDE-3 inhibitors, such as cilostazol, may form the basis of a novel therapeutic strategy for diabetes-associated cognitive impairment or vascular dementia. PMID: 25281785 [PubMed - as supplied by publisher] (Source: Neurobiology of Disease)
Source: Neurobiology of Disease - October 1, 2014 Category: Neurology Authors: Kwon KJ, Lee EJ, Kim MK, Kim SY, Kim JN, Kim JO, Kim HJ, Kim HY, Han JS, Shin CY, Han SH Tags: Neurobiol Dis Source Type: research
Clinical management of esophagogastroduodenoscopy by clinicians under the former guidelines of the Japan Gastroenterological Endoscopy Society for patients taking anticoagulant and antiplatelet medications
Conclusion We revealed the low impact of the 2005 JGES guidelines on the management of antithrombotic drugs. Our physicians have reasonably decided to continue antithrombotic drugs before EGD according to the risk of thromboembolism. (Source: Gastric Cancer)
Source: Gastric Cancer - September 25, 2014 Category: Gastroenterology Source Type: research
PTEN Upregulation May Explain the Development of Insulin Resistance and Type 2 Diabetes with High Dose Statins
Conclusions Long-term ROS can induce diabetes by upregulating PTEN. CIL attenuates these changes. Partial knockdown of PTEN also ameliorates ROS-induced insulin resistance. Further studies are needed to assess the effects of increasing cAMP levels to prevent the induction of diabetes by statins. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - September 25, 2014 Category: Cardiology Source Type: research
EHMTI-0033. The phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cAMP increase
(Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - September 18, 2014 Category: Neurology Source Type: research
The Phosphodiesterase III Inhibitor Cilostazol Ameliorates Ethanol-Induced Endothelial Dysfunction.
Abstract Intracranial hemorrhage (ICH) remains a devastating disease, and heavy alcohol consumption is an underlying risk factor. The aim of this study was to study the mechanism of ethanol-induced endothelial cell damage and to evaluate the protective effect of cilostazol against ethanol-induced damage. We first evaluated transendothelial electrical resistance (TEER) and cell viability of human brain microvascular endothelial cells at the ethanol concentration shown to cause mild-to-moderate intoxication in the clinic. We also assessed the permeability of fluorescein isothiocyanate (FITC)-dextran and the change in...
Source: Current Neurovascular Research - September 12, 2014 Category: Neurology Authors: Takagi T, Mishiro K, Shimazawa M, Yoshimura S, Iwama T, Hara H Tags: Curr Neurovasc Res Source Type: research
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial
DiscussionThis trial will provide powerful insight into whether the design of the COMPLETETM-SE stent is more fracture-resistant or effective in preventing restenosis compared with the SMARTTM CONTROL stent. Also, it will determine the efficacy and safety of aspirin plus clopidogrel versus aspirin plus cilostazol in patients undergoing stent implantation in femoropopliteal lesions.Trial registration: Registered on 2 April 2012 with the National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier# NCT01570803). (Source: Trials)
Source: Trials - September 10, 2014 Category: Journals (General) Authors: Sang ParkSeung RhaCheol ChoiEung KimDong OhYun ChoWoong ChoiSeung LeeYong KimSeung ChoiWon KimKi KimJang ChoJoo KimSang KimJang BaeJung BongWon KangJu BaekJae SeoWoo ChungMahn ParkSung HerJon SuhMin KimYeo KimHwan ChoiJae Soh Source Type: research
A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina
Conclusions Cilostazol is an effective therapy for patients with VSA uncontrolled by conventional amlodipine therapy, and has no serious side effects. Trial registration number NCT01444885. (Source: Heart)
Source: Heart - September 9, 2014 Category: Cardiology Authors: Shin, E.-S., Lee, J.-H., Yoo, S.-Y., Park, Y., Hong, Y. J., Kim, M. H., Lee, J.-Y., Nam, C.-W., Tahk, S.-J., Kim, J.-S., Jeong, Y.-H., Lee, C. W., Shin, H. K., Kim, J.-H. Tags: Coronary artery disease Source Type: research
Disintegration Mediated Controlled Release Supersaturating Solid Dispersion Formulation of an Insoluble Drug: Design, Development, Optimization, and In Vitro Evaluation.
The objective of this study was to develop a solid dispersion based controlled release system for drug substances that are poorly soluble in water. A wax-based disintegration mediated controlled release system was designed based on the fact that an amorphous drug can crystallize out from hydrophilic matrices. For this study, cilostazol (CIL) was selected as the model drug, as it exhibits poor aqueous solubility. An amorphous solid dispersion was prepared to assist the drug to attain a supersaturated state. Povidone was used as carrier for solid dispersion (spray drying technique), hydrogenated vegetable oil (HVO) as wax ma...
Source: AAPS PharmSciTech - September 5, 2014 Category: Drugs & Pharmacology Authors: Verma S, Rudraraju VS Tags: AAPS PharmSciTech Source Type: research
Effect of Cilostazol on the P50 of the Oxygen-Hemoglobin Dissociation Curve
This study was designed to investigate the effect of cilostazol on the P50 of the oxygen hemoglobin dissociation curve. A total of eight healthy adult subjects were studied. Blood samples (0.5 mL) from each subject were mixed with 5, 10, and 20 μL of the 0.5 mg/mL stock solution of cilostazol to give concentrations of 10, 20, and 40 µg/mL equivalent to adult doses of 50, 100, and 200 mg, respectively. The control sample had no drug added. The oxygen hemoglobin dissociation curve of each sample was plotted and the P50 determined with a Hemox-Analyzer (TCS, Medical Products Division, Southampton, PA). The mean P50 for th...
Source: International Journal of Angiology - September 3, 2014 Category: Cardiology Authors: McKoy, MarshalynAllen, KyomiRichards, AndreaPepple, Dagogo Tags: Rapid Communication Source Type: research
Renexin as a rescue regimen for noise-induced hearing loss.
This study was designed to investigate the protective effects of renexin on hearing, the organ of Corti (OC), and medial olivocochlear efferents against noise-induced damage. C57BL/6 mice were exposed to 110 dB SPL white noise for 60 min and then randomly divided into three groups: high- and low-dose renexin-treated groups and noise only group. Renexin were administered for 7 days: 90 mg/kg to the low-dose, and 180 mg/kg to the high-dose groups. All mice, including the controls underwent hearing tests on postnoise day 8 and were killed for cochlear harvest. We compared the hearing thresholds and morphology of the OC and co...
Source: Noise and Health - September 1, 2014 Category: Audiology Authors: Park SY, Back SA, Kim HL, Kim DK, Yeo SW, Park SN Tags: Noise Health Source Type: research
Carotid Plaque Characteristics on Magnetic Resonance Plaque Imaging Following Long-term Cilostazol Therapy
Conclusions: Signal alterations on MR plaque imaging indicated the increase of fibrous components and the decrease of lipid/necrotic components in the carotid plaque during the cilostazol therapy. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - August 29, 2014 Category: Neurology Authors: Mao Yamaguchi Oura, Makoto Sasaki, Hideki Ohba, Shinsuke Narumi, Kazumasa Oura, Ikuko Uwano, Yasuo Terayama Tags: Original Articles Source Type: research
Induction of heme oxygenase‑1 expression protects articular chondrocytes against cilostazol‑induced cellular senescence.
Abstract Chondrocyte senescence is associated with the aging and degeneration of cartilage, and eventually leads to joint destruction. The aim of this study was to elucidate the mechanisms responsible for the cytoprotective effects of heme oxygenase‑1 (HO‑1) on chondrocytes in cartilage. Chondrocyte senescence was induced using cilostazol and measured using a specific senescence‑associated β‑galactosidase (SA‑β‑gal) staining assay. Cilostazol altered the expression of type Ⅱ collagen and β‑catenin, which are phenotypic markers of the differentiation and dedifferentiation of chondrocytes. Cilos...
Source: International Journal of Molecular Medicine - August 29, 2014 Category: Molecular Biology Authors: Kim KM, Park SE, Lee MS, Kim K, Park YC Tags: Int J Mol Med Source Type: research
Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer's Disease: a Translational Overview.
Abstract Phosphodiesterase inhibitors (PDE-Is) enhance cAMP and/or cGMP signaling via reducing the degradation of these cyclic nucleotides. Since both cAMP and cGMP signaling are essential in a variety of cellular functions, including neuroplasticity and neuroprotection, PDE-Is are receiving increased attention as possible targets for treatment of age-related cognitive decline as well as Alzheimer's disease (AD). In this review we will give a translational overview of the preclinical and clinical data on PDE-Is and cognition enhancement focusing on aging and AD. PDE2, 4 and 5 inhibitors improved memory performance ...
Source: Current Pharmaceutical Design - August 26, 2014 Category: Drugs & Pharmacology Authors: Heckman PR, Wouters C, Prickaerts J Tags: Curr Pharm Des Source Type: research
Beneficial effect of cilostazol‐mediated neuronal repair following trimethyltin‐induced neuronal loss in the dentate gyrus
Cilostazol acts as an antiplatelet agent and has other pleiotropic effects based on phosphodiesterase‐3‐dependent mechanisms. We evaluated whether cilostazol would have a beneficial effect on neuronal repair following hippocampal neuronal damage by using a mouse model of trimethyltin (TMT)‐induced neuronal loss/self‐repair in the hippocampal dentate gyrus [Ogita et al. (2005) J Neurosci Res 82:609−621]; these mice will hereafter be referred to as impaired animals. A single treatment with cilostazol (10 mg/kg, i.p.) produced no significant change in the number of 5‐bromo‐2′‐deoxyuridine (BrdU)‐incorporat...
Source: Journal of Neuroscience Research - August 20, 2014 Category: Neuroscience Authors: Masanori Yoneyama, Masayuki Tanaka, Shigeru Hasebe, Taro Yamaguchi, Tatsuo Shiba, Kiyokazu Ogita Tags: Research Article Source Type: research
CILOSTAZOL Tablet [Carilion Materials Management]
Updated Date: Aug 15, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 15, 2014 Category: Drugs & Pharmacology Source Type: news
CILOSTAZOL Tablet [American Health Packaging]
Updated Date: Aug 11, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 11, 2014 Category: Drugs & Pharmacology Source Type: news
CILOSTAZOL Tablet [Preferred Pharmaceuticals, Inc.]
Updated Date: Jul 31, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 31, 2014 Category: Drugs & Pharmacology Source Type: news
Donepezil Can Improve Ischemic Muscle Atrophy by Activating Angiomyogenic Properties of Satellite Cells.
Conclusions:The present results suggest that a clinical dosage of DPZ accelerates angiomyogenesis by directly acting on both endothelial and satellite cells. Therefore, DPZ is a potential additional choice for conventional drug therapy against PAD. PMID: 25070503 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - July 25, 2014 Category: Cardiology Authors: Noguchi T, Kakinuma Y, Arikawa M, Okazaki K, Hoshino E, Iiyama T, Kubo T, Kitaoka H, Doi Y, Sato T Tags: Circ J Source Type: research
CILOSTAZOL Tablet [Teva Pharmaceuticals USA Inc]
Updated Date: Jul 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 24, 2014 Category: Drugs & Pharmacology Source Type: news